(11/4, Fiore) reported, "Adding the direct renin inhibitor aliskiren (Tekturna) to either an angiotensin-receptor blocker (ARB) or an angiotensin-converting-enzyme (ACE) inhibitor didn't reduce heart or kidney events in type 2 diabetes patients at risk for such complications," according to a study (11/5) presented at Kidney Week and published online simultaneously in the New England Journal of Medicine. "In a randomized, controlled trial -- halted after its second interim analysis -- there was no difference in a composite of cardiovascular and renal endpoints for patients who had either the drug or placebo as add-on therapy (18.3% versus 17.1%)," researchers reported. In fact, "the study 'documented more adverse events in the aliskiren group than in the placebo group without clinical benefits to offset them.'"
No comments:
Post a Comment